Clinical trials: Thrombocytopenia Chemotherapy Induced
Chemotherapy-induced Thrombocytopenia, Romiplostim N01
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
- Trial name
- NCT07063225
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pediatric Cancer, Thrombocytopenia
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia
This study evaluates the use of tranexamic acid (TXA) in addition to standard therapy in children receiving chemotherapy or blood and/or marrow transplantation to decrease the risk of bleeding.
- Conditions
- Pediatric Cancer, Thrombocytopenia, Hemostatic Disorder, Coagulation Defect; Acquired
- Trial name
- NCT03806556
- Testing
- Tranexamic Acid, Normal saline
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Meghan McCormick
Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma
A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
The purpose of this study is to identify a well-tolerated, effective dose and schedule of AMG 531 for the treatment of Chemotherapy Induced Thrombocytopenia (CIT) in subjects with lymphoma receiving multi-cycle chemotherapy.
- Conditions
- Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Cancer
- Trial name
- NCT00283439
- Testing
- AMG 531
- Volunteers
- 39 people
- Sponsor
- Amgen
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer
- Trial name
- RECITE (NCT03362177)
- Testing
- Romiplostim
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 165 people
- Sponsor
- Amgen
Thrombopenia, Cervical Cancer
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
Exploring and evaluating the efficacy of herombopag in preventing thrombocytopenia due to radiotherapy for cervical cancer
- Conditions
- Thrombopenia, Cervical Cancer, Radiotherapy Side Effect, Chemotherapeutic Toxicity
- Trial name
- NCT06745219
- Testing
- herombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Epithelial Ovarian Cancer
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
The aim of the current study is to compare weekly versus three-week collective of carboplatin/paclitaxel in advanced epithelial ovarian cancer.
- Trial name
- NCT05963334
- Testing
- Carboplatin/paclitaxel
- Where
- Egypt
- Volunteers
- 49 people
- Sponsor
- Cairo University
Thrombocytopenia, Primary Thrombocytopenia,Unspecified
Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia
The increasing need for blood components and the increasingly careful donor selection procedures, make the availability of blood components very reduced, in particular for platelets that are currently administered preferably…
- Conditions
- Thrombocytopenia, Primary Thrombocytopenia,Unspecified, Thrombocytopenia Chemotherapy Induced
- Trial name
- MICE (NCT02032134)
- Testing
- Transfusion of Pooled Platelets Cryopreserved In DMSO
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Napolitano Mariasanta
Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use
Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma
This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma
- Conditions
- Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use, Lymphoma
- Trial name
- NCT04797182
- Testing
- avatrombopag
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura
A Study of PN20 in Healthy Adult Volunteers
The main aim of this clinical trial is to assess the safety of PN20 in healthy volunteers aged 18 to 50 years. The main questions it aims to answer are: Is PN20 safe in adult? Researchers will compare PN20 to a placebo (a…
- Trial name
- NCT06523088
- Testing
- PN20
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
Chemotherapy-induced Thrombocytopenia, Herombopag
Herombopag for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors
- Trial name
- NCT05236582
- Testing
- Herombopag
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chemotherapy-induced Thrombocytopenia, Solid Malignancy
Romiplostim in Chemotherapy-Induced Thrombocytopenia
Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy
- Trial name
- NCT06201663
- Testing
- Romiplostim
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Thrombocytopenia
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC
Purpose: To evaluate the efficacy and safety of rHuTPO/rHuIL-11 in the treatment for chemotherapy-induced thrombocytopenia in patients with NSCLC receiving gemcitabine and cisplatin or carboplatin chemotherapy.
- Trial name
- NCT02344979
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Chemotherapy-induced Thrombocytopenia
To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment
Chemotherapy-induced thrombocytopenia (CIT) is a common hematological toxicity in patients with solid tumors undergo chemotherapy, which can increase the risk of bleeding, prolong hospital stay, increase medical costs, and even…
- Trial name
- NCT05688306
- Testing
- Recombinant Human Interleukin-11 for Injection
- Where
- China
- Volunteers
- 3,494 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Chemotherapy-Induced Thrombocytopenia
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two…
- Trial name
- NCT01345214
- Testing
- ONO-7746
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 17 people
- Sponsor
- Ono Pharma USA Inc
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00003619
- Testing
- filgrastim, vitamin E, busulfan
- Where
- 2 sites in United States
- Sponsor
- Drexel University College of Medicine
Lung Cancer, Chemotherapy-Induced Thrombocytopenia
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung…
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer
- Trial name
- NCT00413283
- Testing
- Romiplostim, Gemcitabine, Carboplatin
- Where
- 113 sites in United States, Austria and 6 more
- Volunteers
- 63 people
- Sponsor
- Amgen
Chemotherapy-induced Thrombocytopenia
A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor
The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include…
- Trial name
- NCT03049774
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Thrombocytopaenia
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 versus placebo as treatment for patients with…
- Trial name
- NCT00102726
- Testing
- SB497115
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 183 people
- Sponsor
- GlaxoSmithKline
Chemotherapy in Non-Small Cell Lung Cancer
Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)
Chemotherapy is one of the main treatments for advanced NSCLC. However, chemotherapy induced thrombocytopenia (CIT) is one of the most important limitations for subsequent chemotherapy of cancer.
- Trial name
- NCT02650700
- Testing
- spleen radiotherapy
- Volunteers
- 100 people
- Sponsor
- Xinqiao Hospital of Chongqing